When TSI levels go up or down in people with thyroid eye disease, their eye inflammation and physical signs tend to change in the same direction over time.
Claim Context
Changes in serum thyroid-stimulating immunoglobulin (TSI) levels over time correlate with changes in clinical activity scores and orbital measurements in patients with thyroid eye disease, suggesting TSI dynamics may reflect disease progression or remission.
“There was a significant positive correlation between the change in TSI and the change in clinical characteristics like change in Hertel measurements, change in MRD1, and change in PF (P = 0.024, <0.01, <0.01, Pearson correlation). Moreover, there was significant positive correlation between the change in TSI and the change in CAS (P < 0.01, Pearson correlation).”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether serial TSI measurements reliably predict or track disease activity trajectories across different treatment regimens and populations.
A systematic review and meta-analysis of all longitudinal studies measuring TSI at ≥3 time points in thyroid eye disease patients, correlating TSI trends with CAS, imaging, and treatment response, using standardized assays and adjusting for therapy type.
Whether TSI-guided treatment adjustments improve outcomes compared to CAS-guided adjustments.
A multicenter RCT of 150 patients with active thyroid eye disease, randomized to treatment guided by TSI trends (e.g., escalate if TSI rises >20% over 3 months) vs. CAS trends, with primary outcome of time to remission and secondary outcomes of relapse rate and steroid exposure.
Whether TSI trajectory predicts future clinical worsening or improvement independent of treatment.
A prospective cohort study following 200 patients with thyroid eye disease, measuring TSI every 3 months for 2 years, recording all treatments, and using time-to-event analysis to determine if TSI slope predicts CAS escalation or remission.
Whether patients who worsen clinically have significantly different TSI trajectories than those who improve.
A case-control study comparing TSI change over 6 months in 50 patients who progressed (CAS increase ≥2) vs. 50 who improved (CAS decrease ≥2), matched for baseline TSI, age, and treatment, using repeated measures analysis.
Whether TSI levels at a single time point correlate with current disease activity.
A cross-sectional analysis of TSI and CAS in 300 patients with thyroid eye disease at a single visit, using standardized assays and blinded assessments.